Standard

Risico op trombose bij reactieve trombocytose. / Hengeveld, Paul J.; Hazenberg, Mette D.; Biezeveld, Maarten H. et al.

In: Nederlands tijdschrift voor geneeskunde, Vol. 162, No. 41, D2697, 2018.

Research output: Contribution to journal › Article › Professional

Harvard

Hengeveld, PJ, Hazenberg, MD, Biezeveld, MH & Raphael, MF 2018, 'Risico op trombose bij reactieve trombocytose', Nederlands tijdschrift voor geneeskunde, vol. 162, no. 41, D2697.

APA

Hengeveld, P. J., Hazenberg, M. D., Biezeveld, M. H., & Raphael, M. F. (2018). Risico op trombose bij reactieve trombocytose. Nederlands tijdschrift voor geneeskunde, 162(41), [D2697].

Vancouver

Hengeveld PJ, Hazenberg MD, Biezeveld MH, Raphael MF. Risico op trombose bij reactieve trombocytose. Nederlands tijdschrift voor geneeskunde. 2018;162(41):D2697.

Author

Hengeveld, Paul J. ; Hazenberg, Mette D. ; Biezeveld, Maarten H. et al. / Risico op trombose bij reactieve trombocytose. In: Nederlands tijdschrift voor geneeskunde. 2018 ; Vol. 162, No. 41.

BibTeX

@article{ee3b93ceda9e40c287413b245ebcf553,
title = "Risico op trombose bij reactieve trombocytose",
abstract = "Reactive thrombocytosis (RT; thrombocyte count: > 450 x 109/l) is a condition in which an increase in platelet production, stimulated by cytokines in the bone marrow, is secondary to some condition or circumstance. Although RT does often occur in children, the risk of thromboembolic complications is negligible in this group if they have no other risk factors for thrombosis. In the absence of additional risk factors for thrombosis it seems as though RT in adults does not predispose them to thromboembolic complications either. Patients with RT caused by a non-myeloproliferative malignancy do have an increased risk of thromboembolic complications; antithrombotic prophylaxis might be effective in this group, but there is no scientific evidence for this. We advise a watch-and-wait approach in children and adults with RT who have no other risk factors for thromboembolism, even in patients with extreme thrombocytosis (thrombocyte count: > 1000 x 109/l). In patients who do have an increased risk of thromboembolic complications we advise tailoring prescription or non-prescription of antithrombotic prophylaxis to the individual patient.",
author = "Hengeveld, {Paul J.} and Hazenberg, {Mette D.} and Biezeveld, {Maarten H.} and Raphael, {Martine F.}",
year = "2018",
language = "Dutch",
volume = "162",
journal = "Nederlands tijdschrift voor geneeskunde",
issn = "0028-2162",
publisher = "Bohn Stafleu van Loghum",
number = "41",

}

RIS

TY - JOUR

T1 - Risico op trombose bij reactieve trombocytose

AU - Hengeveld, Paul J.

AU - Hazenberg, Mette D.

AU - Biezeveld, Maarten H.

AU - Raphael, Martine F.

PY - 2018

Y1 - 2018

N2 - Reactive thrombocytosis (RT; thrombocyte count: > 450 x 109/l) is a condition in which an increase in platelet production, stimulated by cytokines in the bone marrow, is secondary to some condition or circumstance. Although RT does often occur in children, the risk of thromboembolic complications is negligible in this group if they have no other risk factors for thrombosis. In the absence of additional risk factors for thrombosis it seems as though RT in adults does not predispose them to thromboembolic complications either. Patients with RT caused by a non-myeloproliferative malignancy do have an increased risk of thromboembolic complications; antithrombotic prophylaxis might be effective in this group, but there is no scientific evidence for this. We advise a watch-and-wait approach in children and adults with RT who have no other risk factors for thromboembolism, even in patients with extreme thrombocytosis (thrombocyte count: > 1000 x 109/l). In patients who do have an increased risk of thromboembolic complications we advise tailoring prescription or non-prescription of antithrombotic prophylaxis to the individual patient.

AB - Reactive thrombocytosis (RT; thrombocyte count: > 450 x 109/l) is a condition in which an increase in platelet production, stimulated by cytokines in the bone marrow, is secondary to some condition or circumstance. Although RT does often occur in children, the risk of thromboembolic complications is negligible in this group if they have no other risk factors for thrombosis. In the absence of additional risk factors for thrombosis it seems as though RT in adults does not predispose them to thromboembolic complications either. Patients with RT caused by a non-myeloproliferative malignancy do have an increased risk of thromboembolic complications; antithrombotic prophylaxis might be effective in this group, but there is no scientific evidence for this. We advise a watch-and-wait approach in children and adults with RT who have no other risk factors for thromboembolism, even in patients with extreme thrombocytosis (thrombocyte count: > 1000 x 109/l). In patients who do have an increased risk of thromboembolic complications we advise tailoring prescription or non-prescription of antithrombotic prophylaxis to the individual patient.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85054778685&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30306760

M3 - Article

C2 - 30306760

VL - 162

JO - Nederlands tijdschrift voor geneeskunde

JF - Nederlands tijdschrift voor geneeskunde

SN - 0028-2162

IS - 41

M1 - D2697

ER -

ID: 5756545